| 2023-03-28 | -2.36 % |
- Investors who purchased or acquired Catalent, Inc. (CTLT) securities between August 30, 2021, and October 31, 2022, have an upcoming April 25, 2023 deadline to file a lead plaintiff motion in a class action due to Catalent allegedly making false and/or misleading statements throughout the Class Period, including prematurely recognizing revenue, disregarding regulatory rules, and overstating revenues by $568.2 million, resulting in a significant decline in their stock price.
|
| 2023-03-24 | +2.6 % |
|
| 2023-03-23 | -3.11 % |
|
| 2023-03-22 | -3.19 % |
|
| 2023-03-20 | -0.19 % |
|
| 2023-03-17 | -5.74 % |
|
| 2023-03-16 | +1.95 % |
- A class action lawsuit has been filed against Catalent Inc. on behalf of investors who purchased the company's securities between August 30, 2021, and October 31, 2022, due to the alleged materially false and/or misleading statements of the company during the class period, and consequently the company's stock price went down. The recent increase in the company's stock price is not mentioned in the article, and the reason for the increase is not provided.
- Law firm Kuznicki Law PLLC has issued an alert to shareholders of Catalent, Inc. (CTLT) regarding a securities class action lawsuit, and the stock went up by 1.95% last night.
- Catalent's stock went up by 1.95% after announcing a licensing agreement with Bhami Research Laboratory (BRL) that will enable Catalent to access BRL's formulation technology, which reduces viscosity to aid in the subcutaneous delivery of high-concentration biologic therapies, thus improving patient benefits over traditional intravenous injections.
- The article discusses the best falling stocks to buy now, including stocks such as Baxter International and Dominion Energy, and mentions that the S&P 500 gained 1.68%, the Nasdaq Composite bounced 2.14%, and the Dow rallied 1.06% while the CPI data for February shows signs of inflation cooling off, leading to potential buying opportunities in these falling stocks, according to analysts and hedge funds.
|
| 2023-03-15 | -0.67 % |
|
| 2023-03-14 | +7.07 % |
|
| 2023-03-13 | -3.31 % |
- Law firm Pomerantz LLP is investigating claims of securities fraud and other unlawful practices by Catalent Inc. and certain officers and/or directors, after the company disclosed negative information and reported a decline in earnings, resulting in a drop in stock price.
- Law firm Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc (CTLT) regarding potential securities fraud or other unlawful business practices, following a string of negative events including falling demand for COVID-related products, delayed vaccine releases and regulatory issues at key facilities causing the stock to drop 31.7% to $44.90 a share.
- The article announces that class actions have been commenced on behalf of stockholders of Alico, Inc., Catalent, Inc., Tesla, Inc., and DLocal Ltd, and mentions the lead plaintiff deadline for each case, while also giving some background information about the companies in question; the article does not provide a specific reason for why Catalent (CTLT) stock went down.
- Law firm Lieff Cabraser Heimann & Bernstein is recommending that investors who suffered losses from purchasing or acquiring Catalent securities between August 30, 2021, and October 31, 2022, contact its attorneys immediately regarding a pending securities fraud class action against Catalent, leading to the stock's 3.31% decline. The securities class action alleges that Catalent overstated its revenues and demand for its COVID-19 manufacturing services, and there were numerous operational and safety issues at its Bloomington plant that led the FDA to hold back 10 million doses of Moderna’s COVID-19 vaccine that were filled and packaged at the plant.
- A shareholder has filed a class action against Catalent, Inc. (NYSE: CTLT) for violations of the Securities Exchange Act of 1934, claiming that the company artificially inflated its revenues through fraudulent accounting and channel stuffing schemes, causing the stock to fall more than 68 percent from a record high of $142.64 per share on September 9, 2021, to $44.90 on November 2, 2022. The stock went down by 3.31% last night due to this news.
|
| 2023-03-10 | -2.89 % |
|
| 2023-03-09 | +0.21 % |
- Catalent's CTLT stock went up 0.21% as members of the executive leadership team are scheduled to present at two upcoming investor conferences, including the KeyBanc Life Sciences & MedTech Investor Forum and the Barclays Global Healthcare Conference.
- The article reports on Acorda Therapeutics' financial results for Q4 and full year 2022, including improved operating and financial performance, a substantial AMPYRA arbitration award, renegotiated agreements with Catalent for INBRIJA manufacturing, and launches of INBRIJA in Germany and Spain, which contributed to Catalent's (CTLT) stock going up last night.
- The article does not provide information on why Catalent Inc.'s (CTLT) stock went up by 0.21% last night, but rather informs shareholders about a securities class action lawsuit against the company for false and misleading statements or omission of material information leading to an artificial inflation of the stock during the Class Period of August 30, 2021, to October 31, 2022.
|
| 2023-03-08 | +2.92 % |
|
| 2023-03-07 | -4.95 % |
|
| 2023-03-06 | -3.93 % |
|
| 2023-03-03 | +4.31 % |
|
| 2023-03-02 | +3.16 % |
- Catalent's (CTLT) stock went up by 3.16% after the company announced that its Vice President of Business Transformation and Regional General Manager, Matt Blume, will host a panel session at the upcoming Bio Supply Management Alliance (BSMA) Conference to discuss strategies that enable collaboration and integration of organizations, as well as information in the drug development ecosystem that can reduce time to market, lower cost of development, and improve launch times.
- The stock of Catalent, Inc. (CTLT) went up by 3.16% on March 1, 2023, despite pending class actions which claim that the company was engaged in accounting and channel stuffing schemes, causing its stock price to reach new record highs during the COVID-19 pandemic, which were unsustainable in the long-term.
- The securities litigation law firm of Kuznicki Law PLLC issues an alert to shareholders of Catalent, Inc. (CTLT), and the stock went up 3.16%; however, the article does not provide information on the reason behind the stock increase.
|
| 2023-03-01 | +1.16 % |
|
| 2023-02-28 | +1.46 % |
|
| 2023-02-27 | -1.09 % |
|
| 2023-02-21 | -3.8 % |
|
| 2023-02-15 | -1.79 % |
|
| 2023-02-13 | +0.13 % |
|
| 2023-02-10 | -2.14 % |
|
| 2023-02-07 | +6.84 % |
|
| 2023-02-06 | +19.54 % |
|
| 2023-01-30 | -1.99 % |
|
| 2023-01-24 | -5.74 % |
|
| 2023-01-20 | +0.32 % |
|
| 2023-01-17 | -2.28 % |
|
| 2023-01-12 | -0.22 % |
|
| 2023-01-06 | +3.23 % |
|
| 2023-01-05 | -0.6 % |
|
| 2022-12-22 | -1.04 % |
|
| 2022-12-21 | -2.05 % |
|
| 2022-11-29 | +0.55 % |
|
| 2022-11-03 | -5.9 % |
|
| 2022-11-02 | -9.35 % |
|
| 2022-11-01 | -24.65 % |
|
